Julie Smith

Julie Anne Smith is currently an Independent Director at Exelixis, Inc. since 2016 and an Independent Director at Stoke Therapeutics, Inc. since 2020.
Former roles include President, Chief Executive Officer & Director at Horizon Pharmaceutical LLC; President & Chief Executive Officer at Raptor Pharmaceuticals, Inc. from 2015 to 2016; President, Chief Executive Officer & Director at Nuredis, Inc. from 2017 to 2018; Chief Executive Officer & Director at Nuvig Therapeutics, Inc.; President, Chief Executive Officer & Director at ESCAPE Bio, Inc. from 2018 to 2022; Director-Channel Strategy & Design at Bristol Myers Squibb Co.; Director-Health & Emerging Companies Sections at Biotechnology Innovation Organization; Independent Director at Astellas Gene Therapies, Inc. from 2016 to 2020; Vice President-Commercial at Jazz Pharmaceuticals, Inc. from 2006 to 2008; Vice President-Global Marketing at Genzyme General from 2001 to 2005; Head-Operations & Business Development at Novazyme Pharmaceuticals, Inc. from 2000 to 2001; and Chief Commercial Officer & Vice President at Enobia Pharma, Inc. from 2008 to 2012.
Education includes undergraduate studies at Cornell University.